Ensysce Biosciences Inc ENSC completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection, PF614-MPAR.
The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR reduced opioid delivery when three or more doses were consumed simultaneously.
The company says that PF614-MPAR is the first drug that can limit opioid exposure when too many pills are swallowed, protecting against overdose.
In the PF614-MPAR-101 study, the data showed that a 25 mg dose of PF614-MPAR delivered oxycodone as designed for what may be a prescribed dose of one to two capsules.
When administering three or more capsules simultaneously, the amount of opioid released and absorbed into the circulation diminished compared to the unprotected PF614, substantially reducing the risk of overdose.
Opioids are used widely for severe pain, such as in patients fighting cancer and post-operative pain. Opioids are highly effective but carry a significant risk of abuse, addiction, and overdose.
Price Action: ENSC shares are up 23.80% at $4.26 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
